- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02243969
Alpha-linolenic Acid and Blood Pressure (VASALA)
Effects of Alpha-linolenic Acid on 24h-ambulatory Mean Arterial Pressure in Untreated High-normal and Stage I Hypertensive Subjects
Rationale: Increased intakes of n-3 long chain polyunsaturated fatty acids eicosapentanoic acid (EPA) and docosahexaenoic acid (DHA), mainly found in fatty fish, are recommended for the prevention of coronary heart disease. Alpha-linolenic acid (ALA, C18:3n-3) is the most common vegetable-oil based n-3 fatty acid. Evidence exists that ALA supplementation can also have a protective effect on the development on cardiovascular disease, but may exert its cardio protective effects through different routes. The benefit may (partly) be due to blood pressure lowering. However, evidence for beneficial effects of ALA on blood pressure is conflicting. Therefore, we propose to investigate the effect of flaxseed oil, high in ALA, using a study powered on 24-hour blood pressure, in a population with high normal blood pressure and mild hypertension.
Objective: To study the effects of flaxseed oil, rich in ALA on 24h-ambulatory mean arterial pressure (MAP) in men and women with high-normal blood pressure and mild hypertension compared to high oleic sunflower oil, poor in ALA.
Study design: Using a double blind randomized, placebo-controlled parallel design, subjects will receive at random daily 10 g of flaxseed oil or a high-oleic acid sunflower oil (HOSF) as control for twelve weeks, with a run-in period of 14 days in advance.
Study population: 72 men and women, aged 40-70 years, with untreated high-normal blood pressure and stage I hypertension and a body mass index between 25 and 35 kg/m2 will participate in the run-in and intervention period. It is estimated that 144 subject have to be screened to find 72 subjects that will enter the run-in period.
Intervention: During the run-in period, subjects will receive daily 10 g of palm super olein oil. During the intervention period subjects receive either 10 g of HOSF or flaxseed oil. All oils are provided in bottles of 5 g, one will be consumed at breakfast or lunch and one at dinner.
Main study parameters/endpoints: The main study parameter is the change in 24h-ambulatory mean arterial pressure (MAP)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Limburg
-
Maastricht, Limburg, Netherlands, 6229 ER
- Maastricht University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Quetelet-index between 25-35 kg/m2
- High-normal blood pressure defined as systolic blood pressure between 130-139 mmHg and/or diastolic blood pressure between 85-89 mmHg. Or stage I hypertension defined as systolic blood pressure between 140-159 mmHg and/or diastolic blood pressure between 90-99 mmHg.
- Mean serum total cholesterol/HDL cholesterol ratio < 8
- Mean serum triacylglycerol < 4.5 mmol/L
- Mean plasma glucose < 7.0 mmol/L
Exclusion Criteria:
- Unstable body weight (weight gain or loss >2 kg in the past 3 months)
- Use of antihypertensive or anticoagulant medication
- Indication for treatment with medication according to the Standard for cardiovascular risk management of the Dutch general practitioners community (NHG)
- Usage of non-steroidal anti-inflammatory drugs (such as aspirin, ibuprofen, naproxen) and not able or willing to stop taking them from at least 4 weeks prior to the study
- Use of medication or a diet known to affect serum lipid or glucose metabolism
- Women with expected changes in the use of oral contraceptives or estrogen replacement therapy during the study period
- Women lactating, pregnant or intend to become pregnant during study
- Active cardiovascular disease like congestive heart failure or recent (<6 months) event (acute myocardial infarction, cerebro vascular accident)
- Severe medical conditions that might interfere with the study such as diabetes mellitus, epilepsy, asthma, chronic obstructive pulmonary disease, inflammatory bowel diseases and rheumatoid arthritis
- Smoking or recently quit smoking (<1 years)
- Abuse of drugs
- More than 21 alcohol consumptions per week for men and 14 consumptions for women
- Reported intense sporting activities > 10 h/w
- Not possible or difficult to venipuncture as evidenced during the screening visits
- Use of an investigational product within the previous 30 days
- Not willing to stop the consumption of vitamin supplements, fish oil capsules or products rich in plant stanol or sterol esters 3 weeks before the start of the study
- Not willing to give up being a blood donor (or having donated blood) from 8 weeks before the start of the study and during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: flaxseed oil (rich in α-linolenic acid )
|
The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
|
Placebo Comparator: high oleic sunflower oil
|
The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
24h-ambulatory mean arterial pressure (MAP)
Time Frame: Baseline and end of intervention period (week 2 and 14)
|
Ambulatory blood pressure measurements will be performed using an automated blood pressure device with 15-minute intervals during the day and 30-minute intervals during the night.
|
Baseline and end of intervention period (week 2 and 14)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postprandial flow mediated dilatation (FMD)
Time Frame: End of intervention period (week 14)
|
The brachial artery FMD will be measured in a subset (n=20 per group) of the study population.
FMD will be measured before and 2 hours after a fat load.
|
End of intervention period (week 14)
|
Night, day and early morning 24h-ambulatory MAP, SBP and DBP
Time Frame: Baseline and end of intervention (week 2 and 14)
|
Ambulatory blood pressure measurements will be performed using an automated blood pressure device with 15-minute intervals during the day and 30-minute intervals during the night.
|
Baseline and end of intervention (week 2 and 14)
|
Systolic, diastolic and MAP office blood pressure
Time Frame: Measured every visit (week 1,2,8,14)
|
Each visit blood pressure will be measured in four-fold with 1-minute interval (the first measurement will be discarded and the last three measurement will be averaged) using a calibrated device.
|
Measured every visit (week 1,2,8,14)
|
The fatty-acid profile of plasma phospholipids
Time Frame: Baseline and end of intervention period (week 2 and 14)
|
measured in fasting plasma samples
|
Baseline and end of intervention period (week 2 and 14)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulse wave velocity (PWV)
Time Frame: Baseline and end of intervention period (week 2 and 14)
|
PWV will be determined by extending data from standard brachial artery blood pressure measurements
|
Baseline and end of intervention period (week 2 and 14)
|
Retinal microvasculature
Time Frame: Baseline and end of intervention period (week 2 and 14)
|
Measured as AV-ratio and vessel diameter from digitized analogue fundus photographs
|
Baseline and end of intervention period (week 2 and 14)
|
Fasting and postprandial lipid and glucose metabolism
Time Frame: Every visit (week 1,2,8,14) Postprandial in subset of n=20 per group
|
Postprandial glucose at time point 15,30,45,60,90,120,180,240 minutes Postprandial lipids at time point 60, 120, 180, 240 minutes
|
Every visit (week 1,2,8,14) Postprandial in subset of n=20 per group
|
Fasting and postprandial serum biomarkers for low-grade systemic inflammation (hsCRP, IL-6) and endothelial function (sICAM-1, VCAM-1, MCP-1 and sE-Selectin)
Time Frame: Every visit (week 1,2,8,14) Postprandial in subset of n=20 per group at time point 60, 120, 240 minutes
|
Every visit (week 1,2,8,14) Postprandial in subset of n=20 per group at time point 60, 120, 240 minutes
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEC 13-3-064
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Flaxseed oil
-
Harvard School of Public Health (HSPH)CompletedCardiovascular Disease
-
Réseau de Santé Vitalité Health NetworkCompleted
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
University of North Carolina, Chapel HillCompletedEffect of Fatty Acids on Memory Performance of ToddlersUnited States
-
University of PennsylvaniaCompletedInflammation | Cystic Fibrosis | Oxidative StressUnited States
-
Huazhong University of Science and TechnologyNot yet recruitingElevated Blood Sugar
-
Universidade Federal do Rio de JaneiroConselho Nacional de Desenvolvimento Científico e Tecnológico; Rio de Janeiro...Unknown
-
Stanford UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedHypertension | Obesity | Insulin Resistance | HypertriglyceridemiaUnited States
-
Zhejiang UniversityNational Natural Science Foundation of ChinaUnknownGestational DiabetesChina
-
Zhejiang UniversityNational Natural Science Foundation of ChinaCompletedInsulin Resistance | Type 2 DiabetesChina